The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 45 results
April 2021
-
Media Release
Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still’s disease
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still’s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening… -
Media Release
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)i
Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell… -
Media Release
Novartis in Canada named a Top 50 Best Workplace™ in the country
Open feedback by Novartis associates contributed to coveted Canadian employer recognition Novartis ranked among the companies with the highest levels of trust and most inclusive cultures in the…
March 2021
-
Media Release
Health Canada approves Kesimpta®, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis (RRMS)
Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing… -
Media Release
Novartis’ KISQALI® (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
KISQALI® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners…
June 2020
-
Media Release
Statement from Novartis on AVXS-101 filing with Health Canada
June 18, 2020 – Dorval - Novartis Pharmaceuticals Canada Inc. is pleased to announce the filing of a marketing application to Health Canada for AVXS-101 (onasemnogene abeparvovec), known in the US… -
Media Release
Long-term, relapse-free survival data for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery presented at ASCO20
More than half of patients with BRAF-mutated advanced melanoma treated with Tafinlar + Mekinist were alive and free of a relapse at five years1 Study conclusions drawn from the five-year follow-up…